MetaCap

Coherus Oncology (CHRS) vs Neumora Therapeutics (NMRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Coherus Oncology (CHRS) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 68.1% versus a loss of 85.7%. Neumora Therapeutics is the larger company by market cap ($63.0 million vs $57.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CHRS-68.12%NMRA-85.67%
+126%+15%-96%
Nov 21, 20251 yearNov 20, 2026
CHRS-92.48%NMRA-97.95%
+28%-38%-104%
Sep 11, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CHRS versus NMRA key metrics
MetricCHRSNMRA
Share price$0.3698$0.3339
Market cap$57.15M$63.01M
1-day change-4.47%-3.78%
YTD return-73.96%-81.35%
1-year return-68.12%-85.67%
5-year return-97.99%—
EPS (TTM)$-1.12$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.17M—
Revenue growth (YoY)+59.81%—
Net income (latest FY)$168.02M$-236.93M
Gross margin67.24%—
Operating margin-429.51%—
Net margin398.43%—
52-week high$2.62$3.65
52-week low$0.3628$0.301
Distance from 52-week high-85.86%-90.85%
Analyst consensusstrong_buybuy
Avg. price target upside+1995.73%+1696.95%
Average volume1.80M1.69M
Shares outstanding154.54M188.69M
Employees14463
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CHRS has outperformed NMRA by 17.5 percentage points over the past year.

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About Neumora Therapeutics

NMRA stock →

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees

CHRS vs NMRA FAQ

Which is bigger, Coherus Oncology or Neumora Therapeutics?

Neumora Therapeutics (NMRA) is larger, with a market capitalization of $63.01M compared with $57.15M for Coherus Oncology (CHRS).

Which stock has performed better over the past year, CHRS or NMRA?

CHRS returned -68.12% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.

Are Coherus Oncology and Neumora Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons